LMATLeMaitre Vascular, Inc.
Price
-9.5%1YEnd-of-day closes, not the intraday tick.
More going right than wrong
Quality strong, no red flags, price roughly fair, growing in the filings, the market undecided.
We are a global provider of medical devices and human tissue cryopreservation services largely used in the treatment of peripheral vascular disease, end-stage renal disease, and cardiovascular disease. We develop, manufacture, and market vascular devices to address the needs of vascular surgeons and, to a lesser degree, other specialties such as cardiac surgeons, general surgeons, and neurosurgeons. Our diversified portfolio of devices consists of brand name products that are used in arteries and veins and are well known to vascular surgeons.
In the company’s own words · 10-K filed Feb 26, 2026 · SEC EDGAR
Charts
As reported to the SEC, without any scoring.
LeMaitre Vascular, Inc. (LMAT) reported revenue of $70M in Q2 2026 (quarter ended Jun 30, 2026), up 9.6% from the same quarter a year earlier. That came with a gross margin of 72% and net income of $17M (24% of revenue). For the full year FY2025, revenue was $250M (+14% year on year) and net income $58M. Its largest region in Q2 2026 was United States at $38M, 54% of the disclosed total, well ahead of Other Countries at 26%. The next results filing is expected around Nov 5, 2026, the same week as a year ago.
What the company said
The company's own words from its current reports to the SEC, newest first
- Aug 4, 2026LeMaitre Q2 2026 Financial Results.Earnings release · press release
- May 5, 2026LeMaitre Q1 2026 Financial Results.Earnings release · press release
- Apr 14, 2026On April 8, 2026, Bridget Ross notified the Board of Directors (the “Board”) of LeMaitre Vascular, Inc. (the “Company”) of her intent not to stand for re-election as a Class II director of the Company at the Company’s 2026 Annual Meeting of Stockholders to be held on June 2, 2026 (the “2026 Annual Meeting”)Director or officer change · Form 8-K
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
Business segments
Jun 2026 · $70.4MThe company’s own SEC segment disclosure.
- United States$38.3M54%
- Other Countries$18.5M26%
- Germany$5.3M8%
- Canada$4.6M6%
- United Kingdom$3.7M5%
Why these answers
Each answer with the checks it was read from. Open one for the numbers.
Conflicts between checks are named, never averaged, and thin data says so.
Medical Instruments & Supplies
Ranks #2 of 21 by RyuScore